IXCHIQ
Chikungunya virus, live attenuated
0.5 mL · powder for solution · intramuscular · authorized from 12 years; not recommended at 65 and older
Chikungunya
Chikungunya
IXCHIQ
One dose, only after a travel-health assessment. Every product below is a Health Canada authorized vaccine; every schedule comes from the Canadian Immunization Guide.
- Products
- 1
- Dose schedules
- 1
- Guidance checked
- 2026-09-27
Authorized products
Brand names and DINs (Drug Identification Numbers) as Health Canada's Drug Product Database lists them. The product monograph is the manufacturer's full prescribing information approved by Health Canada.
Before and after vaccination
- Bring your immunization record so earlier doses can be checked.
- Discuss a serious reaction to a previous vaccine, relevant health conditions, medicines and allergies before receiving a dose.
- After vaccination, stay where you can be observed for at least 15 minutes and report feeling faint or signs of an allergic reaction right away.
- Keep the vaccine name, date and dose in your immunization record.
Based on the Canadian Immunization Guide's administration practices and acute reactions guidance.
Pregnancy & breastfeeding
Pregnancy
Generally contraindicated: a live vaccine. Avoid pregnancy for one month after vaccination.
Breastfeeding
Limited data; an individual assessment with a healthcare provider.
Source: Immunization in pregnancy and breastfeeding: Canadian Immunization Guide — Chapter updated August 2026. Live vaccines are generally contraindicated in pregnancy; routinely recommended vaccines can be given while breastfeeding unless the chapter says otherwise.
How many doses
The schedules the Canadian Immunization Guide describes for this vaccine. Which one applies depends on age, health and product — use the dose planner to see the dates for your situation.
Chikungunya (IXCHIQ) — adults 18 to 64, one dose after a travel-health assessment
1 doseOne dose of live chikungunya vaccine; not routinely recommended, considered only for people at high risk of exposure.
CATMAT: IXCHIQ is generally not recommended for adults 18 to 64 years of age but may be considered for individuals at high risk of infection; it is not recommended at 65 years of age and older (serious adverse events, including deaths, reported mostly in older adults). Health Canada authorizes it from 12 years. Contraindicated in pregnancy and with a weakened immune system.
ProductsIXCHIQ
References and product information
- Chikungunya vaccine: Canadian Immunization Guide — Chapter published February 2026 · updated July 2026
- Vaccine administration practices: Canadian Immunization Guide
- Anaphylaxis and other acute reactions: Canadian Immunization Guide
- Health Canada Drug Product Database — product records and monographs
- Pharmasist vaccine reference: IXCHIQ
Clinical rules reviewed on 2026-09-27. General information from public Canadian guidance; a personal assessment is needed for treatment decisions. Care365 does not decide whether a vaccine is publicly funded in Ontario.